Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss

Prostate Cancer and Prostatic Diseases

Volumn 5, Issue 4, 2002, Pages 304-310

  Preston, D M ^a,b   Torrens J I ^a   Harding, P ^a   Howard, R S ^a   Duncan, W E ^a   Mcleod, David G ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Androgen deprivation; Bone loss; Prostate cancer

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ANALYTICAL ERROR; ANAMNESIS; ANEMIA; ARTICLE; BONE DENSITY; BONE DISEASE; BONE MINERAL; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; FEMUR NECK; FOREARM; HIP; HOT FLUSH; HUMAN; LABORATORY TEST; LIBIDO DISORDER; LUMBAR SPINE; MALE; MUSCLE WEAKNESS; ORCHIECTOMY; OSTEOLYSIS; OSTEOPOROSIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY;

ADENOCARCINOMA; AGED; AMINO ACIDS; ANDROGEN ANTAGONISTS; ANDROGENS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; CALCIUM; DENSITOMETRY, X-RAY; DRUG THERAPY, COMBINATION; FLUTAMIDE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; LEUPROLIDE; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; OSTEOPOROSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 0036970805     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500599     Document Type: Article

References (26)

1. Crawford ED et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-424.
2. Daneshgari F, Crawford ED. Endocrine therapy of advanced carcinoma of the prostate. Cancer 1993; 71: 1089-1097.
3. Garnick MB. Hormonal therapy in the management of prostate cancer: from Huggins to the present. Urology 1997; 49S: 5-15.
4. Sharifi R, Soloway M. Leuprolide Study Group: clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J Urol 1990; 143: 68-71.
5. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439-444.
6. Laufer M et al. Combined androgen blockade for the treatment of patients with metastatic prostate cancer: summary of 15y of clinical research. AUA update series Lesson 29 1999; Vol. XVIII.
7. Moul JW. Contemporary hormonal management of advanced prostate cancer. Oncology 1998; 12: 499-505.
8. Ornstein DK et al. Evaulation and management of the man who has failed primary curative therapy for prostate cancer. Urol Clin North Am 1998; 25: 591-601.
9. Orwoll ES, Klein RF. Osteoporosis in men. Endocrine Reviews 1995; 16: 87-116.
10. Townsend MF et al. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997; 79: 545-550.
11. McGrath S, Diamond T. Osteoporosis as a complication of orchiectomy in two elderly men with prostatic cancer. J Urol 1995; 154: 535-536.
12. Collinson MP, Tyrell CJ, Hutton C. Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate. Calcif Tissue Int 1994; 54: 327-328.
13. Goldray D et al. Decreased bone mineral density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab 1993; 76: 288-290.
14. Stepan J et al. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989; 69: 523-527.
15. Daniell H et al. Progressive osteoporosis during androgen deprivation for prostate cancer. J Urol 2000; 163: 181-186.
16. Wei JT et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 1999; 54: 607-611.
17. Maillefert JF et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999; 161: 1219-1222.
18. Diamond T et al. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Cancer 1998; 83: 1561-1566.
19. Kiratli BJ et al. Progressive decrease in bone density over 10 y of androgen deprivation therapy in patients with prostate cancer. Urology 2001; 57: 127-132.
20. Angus RM et al. A simple method for assessing calcium intake in caucasian women. J Am Diet Assoc 1989;89:209-214.
21. Kelepouris N et al. Severe osteoporosis in men. Ann Inter Med 1995; 123: 452-460.
22. Baillie SP et al. Pathogenesis of vertebral crush fractures in men. Age and Aging 1992; 21: 139-141.
23. Oefelein MG et al. Skeletal fractures associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001; 166: 1724-1728.
24. Diamond TH et al. The antiosteoporotic efficacy of intraveneous pamidronate in men with prostate carcinoma receiving combined androgen blockade. Cancer 2001; 92: 1444-1450.
25. Smith MR et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-955.
26. Reeve J et al. Determinants of the first decade of bone loss after menopause at spine, hip and radius. Q J Med 1999; 92: 261-273.